Trevi Therapeutics up 57% on advancement of key programs [Seeking Alpha]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Seeking Alpha
Healthcare | On the Move Trevi Therapeutics up 57% on advancement of key programs Mar. 16, 2020 3:44 PM ET Trevi Therapeutics, Inc. (TRVI) Douglas W. House Ultra-thinly traded nano cap Trevi Therapeutics ( +56.8% Q4 report The Phase 2b/3 PRISM Enrollment is underway in a Phase 2 clinical trial, CANAL Nalbuphine ER is an orally administered extended-release formulation of nalbuphine, a mixed ?-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. Nalbuphine is the only opioid approved in the U.S. (and most of Europe) that is not classified as a controlled substance since it blocks µ-opioid receptors which are responsible for the euphoric effects of opioids. K-opioid receptors play a key role in itching, coughing and certain movement disorders. See all stocks on the move » Now read: Bully For BioDelivery Sciences »
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics Announces Pricing of $50 Million Underwritten OfferingPR Newswire
- Trevi's chronic cough trial in IPF subjects continues without sample size change [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target raised by analysts at HC Wainwright from $6.00 to $7.50. They now have a "buy" rating on the stock.MarketBeat
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.MarketBeat
TRVI
Earnings
- 11/6/24 - Miss
TRVI
Sec Filings
- 12/17/24 - Form 4
- 12/16/24 - Form 8-K
- 12/16/24 - Form 424B5
- TRVI's page on the SEC website